Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20M | -12M | -9M | -7M | -3M |
| EBITDA | -20M | -12M | -9M | -7M | -1M |
| Net Income | -36M | -12M | -9M | -8M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.81
+5.25% today
1Y Change
+82.39%
Window
Jun 26, 2025 → Jun 15, 2026
Coverage: 243 bars · Jun 26, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Canton Strategic Holdings Inc (CNTN) is a Healthcare stock with a market cap of $110.00M. The stock last traded around $2.81 and up 82.4% across the available one-year price window (Jun 26, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +88.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +88.1%, free cash flow -47.9% with operating margin 0.0% and ROIC -3.3%. Stock Foundry combines CNTN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTN Max Drawdown
-71.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CNTN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.2M
+74.0% YoY
Free Cash Flow
-$1.1M
+83.4% YoY
Revenue Growth
+0.0%
EPS Growth
+88.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20M | -12M | -9M | -7M | -3M |
| EBITDA | -20M | -12M | -9M | -7M | -1M |
| Net Income | -36M | -12M | -9M | -8M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 4M | 11M | 7M | 4K |
| Total Assets | 519M | 4M | 11M | 7M | 622K |
| Total Liabilities | 121M | 2M | 2M | 1M | 5M |
| Shareholder Equity | 398M | 1M | 9M | 6M | -5M |
| Total Debt | 0 | 0 | 0 | 0 | 2M |
| Net Debt | -17M | -4M | -11M | -7M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+83.4% YoY
Capital Expenditures
0
Free Cash Flow
1M
+83.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.